Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted User Fees FDA

QUOTED. Scott Whitaker.

  • Analysis

Executive Summary

The US FDA and the medtech industry missed a 15 January deadline to send a user fee agreement to Congress, but AdvaMed CEO Scott Whitaker says he remains optimistic a deal will be reached soon.

“This past year has been challenging for FDA, and for all of us, frankly. So, these are different times and, as a result, have created new challenges. We, the medtech industry, are working through all these issues to better understand what the needs are going forward. The team at FDA is working hard alongside us to find consensus on several remaining issues – and I’m optimistic and confident that we will reach a resolution soon.” – Scott Whitaker, CEO, AdvaMed

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted User Fees FDA
Latest Headlines

It’s Been Over 1100 Days Since MCIT, Still No TCET In Sight

Mini-Slings Are Comparable To Traditional Ones To Treat Incontinence, FDA Says

Ekso's Exoskeleton Receives Medicare Coverage, Paves Way To Faster Rehabilitation

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

See All
UsernamePublicRestriction

Register

MT144954

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By